HRT Financial’s vTv Therapeutics VTVT Stock Holding History

HRT Financial’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-420	Closed	-$10K	–	3263
2022 Q4	$10K	Buy	+420	New	+$13.9K	﹤0.01%	2224
2021 Q3	–	Sell	-6,081	Closed	-$554K	–	3808
2021 Q2	$554K	Buy	+6,081	New	+$616K	0.01%	1665

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

HRT Financial's VTVT Position: Q1 2023 in Review

HRT Financial sold out of vTv Therapeutics (VTVT) in Q1 2023, closing a stake of 420 shares — an estimated $10K sold.

HRT Financial first reported a position in VTVT in Q2 2021 and held it in 2 quarters. The position peaked at $554K in Q2 2021. 24 funds tracked by Wall St. Rank hold VTVT as of Q1 2023.

HRT Financial reported no remaining vTv Therapeutics position as of Q1 2023 after selling out during the quarter.
HRT Financial sold 420 vTv Therapeutics shares in Q1 2023, an estimated $10K.
HRT Financial first reported a position in vTv Therapeutics in Q2 2021 and held it in 2 quarters.
HRT Financial's vTv Therapeutics position peaked at $554K in Q2 2021.
24 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.